Rapid RT-qPCR testing
A PCR (polymerase chain reaction) rapid test applies DNA/RNA identification technology to accurately identify the genetic markers of the SARS-CoV-2 virus. Globally recognized as the “gold standard” for accurate COVID-19 testing, RT-qPCR rapid tests are available for point-of-care use in Canada. RT-qPCR tests are required to confirm antigen results and also meet many international travel requirements.
The Hyris bCUBE is Health Canada-authorized* for point-of-care testing
*Authorized by Interim Order
Hyris bCUBE RT-qPCR Test
Songbird’s preferred PCR testing device is the Hyris bCUBE. Validated by Health Canada at 100% sensitivity and specificity at 99%, the bCUBE, as a RT-qPCR-based device, it is unmatched for its high sensitivity, often detecting infection in asymptomatic carriers. Authorized by Health Canada for point-of-care (onsite) testing in September 2020, the bCUBE is the chosen testing device by leading Canadian businesses, organizations, and communities, including the Province of Manitoba.
- PCR test
Ideal deployments for PCR rapid tests
Different rapid tests serve different purposes. As national experts in point-of-care rapid test deployments, Songbird will help determine which tests—PCR/NAAT, antigen and/or antibody—are the right fit for a space and its population.
Each type of test has a different probability for detecting COVID-19. As the most sensitive and accurate diagnostic tool, RT-qPCR rapid tests are ideal for meeting travel requirements and in controlled environments where an outbreak will have severe economic and/or health impacts.